Primary Outcome Measures :
Frequency of sustained hypoxemia or hypotension [4 hours ]
Secondary Outcome Measures :
Changes in vital signs [Up to 7 days ]
Changes in blood safety laboratories [Up to 7 days ]
Ventilator-free days [28 days ]
ICU-free days [28 days ]
Total length of hospital stay 28 days ]
All-cause mortality [28 days ]
Changes in levels of oxygenation [Up to 28 days ]
Changes in positive end-expiratory airway pressure [Up to 28 days ]
Changes in respiratory physiologic measures including lung compliance and airway resistance (peak and plateau pressures) [Up to Day 365 ]
All-cause mortality [Up to Day 365 ]
Other Outcome Measures:
Changes in exploratory blood inflammatory markers Up to 7 days ]
Changes in exploratory blood immune markers [Up to 7 days ]
Quality of Life (QoL) [ Up to 365 days ]
>>653
引けには1.34 USD +0.020 (+1.52%)になっているような・・・
p値が報告されていないからなんでしょうか。以前の発表には、人数が少ないため、効果を判定することはできないともこの研究に関して言及しています。調査項目も多いです。
いちいちアサーシスの発表にはツッコミ処が多い気がします・・・
Primary Outcome Measures :
Frequency of sustained hypoxemia or hypotension [4 hours ]
Secondary Outcome Measures :
Changes in vital signs [Up to 7 days ]
Changes in blood safety laboratories [Up to 7 days ]
Ventilator-free days [28 days ]
ICU-free days [28 days ]
Total length of hospital stay 28 days ]
All-cause mortality [28 days ]
Changes in levels of oxygenation [Up to 28 days ]
Changes in positive end-expiratory airway pressure [Up to 28 days ]
Changes in respiratory physiologic measures including lung compliance and airway resistance (peak and plateau pressures) [Up to Day 365 ]
All-cause mortality [Up to Day 365 ]
Other Outcome Measures:
Changes in exploratory blood inflammatory markers Up to 7 days ]
Changes in exploratory blood immune markers [Up to 7 days ]
Quality of Life (QoL) [ Up to 365 days ]